SPECIAL SECTION: LETTER TO THE EDITOR
Reply
Paul Sorajja, MD and
Steve R. Ommen, MD
Division of Cardiovascular Disease and Internal Medicine, Mayo Clinic, 200 1st St. SW, Rochester, MN, USA 55905
ommen.steve{at}mayo.edu
We appreciate the interest of Drs. Mohiddin and Fananapazir in our recent publication on myocardial bridging in adult patients with hypertrophic cardiomyopathy (HCM) (1). We apologize for any misrepresentation of the data from their publication on myocardial bridging in pediatric patients with HCM (2). The study published by Mohiddin et al. was included in the list of references that associated bridging with perfusion abnormalities, as their study had demonstrated such an association in univariate analyses. We emphasized the absence of this relation, in their study, after adjustment for other clinical variables in order to support our conclusions that bridging is not associated with an adverse prognosis.
Septal artery compression was not examined in our study. However, it is unlikely that this finding would be associated with adverse outcomes as such compression is found in nearly all patients with epicardial bridging, and there were no differences with respect to ventricular tachycardia or prognosis in the investigators' study (2). We observed no difference in maximal left ventricular wall thickness between patients with and without bridging. Finally, the study by Drs. Mohiddin and Fananapazir did examine 57 pediatric HCM patients, of whom 23 had myocardial bridging. We apologize for this typographical error.
 |
References
|
|---|
1. Sorajja P, Ommen SR, Nishimura RA, et al. Myocardial bridging in adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003;42:889–894[Abstract/Free Full Text]
2. Mohiddin SA, Begley D, Shih J, Fananapazir L. Myocardial bridging does not predict sudden death in children with hypertrophic cardiomyopathy but is associated with more severe cardiac disease. J Am Coll Cardiol. 2000;36:2270–2278[Abstract/Free Full Text]
|
Top
References